Glycosylation of Therapeutic IgGs

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 67-89

  Mimura, Yusuke ^a   Jefferis, Roy ^b   Mimura Kimura, Yuka ^c   Abrahams, Jodie ^c   Rudd, Pauline M ^d  

^a NATIONAL SANYO HOSPITAL   (Japan)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NATIONAL INSTITUTE FOR BIOPROCESSING RESEARCH AND TRAINING   (Ireland)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Homogeneous Fc glycoform preparation; IgG glycosylation in diseases; Therapeutic IgGs glycosylation

Indexed keywords

EID: 84890986017     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch3     Document Type: Chapter

References (116)

1. Alavi, A., A.J. Pool, and J.S. Axford. 2005. New insights into rheumatoid arthritis associated glycosylation changes. Adv. Exp. Med. Biol. 564:129-138.
2. Arnold, J.N., C.M. Radcliffe, M.R. Wormald, L. Royle, D.J. Harvey, M. Crispin, R.A. Dwek, R.B. Sim, and P.M. Rudd. 2004. The glycosylation of human serum IgD and IgE and the accessibility of identified oligoman-nose structures for interaction with mannan-binding lectin. J. Immunol. 173(11):6831-6840.
3. Arnold, J.N., M.R. Wormald, R.B. Sim, P.M. Rudd, and R.A. Dwek. 2006. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25:21-50.
4. Asano, M., K. Furukawa, M. Kido, S. Matsumoto, Y. Umesaki, N. Kochibe, and Y. Iwakura. 1997. Growth retardation and early death of beta-1,4-galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells. EMBO J. 16(8):1850-1857.
5. Axford, J.S., L. Mackenzie, P.M. Lydyard, F.C. Hay, D.A. Isenberg, and I.M. Roitt. 1987. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet 330(8574):1486-1488.
6. Baker, K.N., M.H. Rendall, A.E. Hills, M. Hoare, R.B. Freedman, and D.C. James. 2001. Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol. Bioeng. 73(3):188-202.
7. Bigge, J.C., T.P. Patel, J.A. Bruce, P.N. Goulding, S.M. Charles, and R.B. Parekh. 1995. Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal. Biochem. 230(2):229-238.
8. Bole, D.G., L.M. Hendershot, and J.F. Kearney. 1986. Posttranslational association of immunoglobulin heavy chain binding protein with nascent heavy chains in nonsecreting and secreting hybridomas. J. Cell. Biol. 102(5):1558-1566.
9. Bruhns, P., A. Samuelsson, J.W. Pollard, and J.V. Ravetch. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18(4):573-581.
10. Burton, D.R., and R.A. Dwek. 2006. Immunology. Sugar determines antibody activity. Science 313(5787): 627-628.
11. Burton, D.R., and J.M. Woof. 1992. Human antibody effector function. Adv. Immunol. 51:1-84.
12. Butler, M., D. Quelhas, A.J. Critchley, H. Carchon, H.F. Hebestreit, R.G. Hibbert, L. Vilarinho, E. Teles, G. Matthijs, E. Schollen, and others. 2003. Detailed glycan analysis of serum glycoproteins of patients with congenital disorders of glycosylation indicates the specific defective glycan processing step and provides an insight into pathogenesis. Glycobiology 13(9):601-622.
13. Canfield, S.M., and S.L. Morrison. 1991. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 173(6):1483-1491.
14. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99(3):754-758.
15. Chappel, M.S., D.E. Isenman, M. Everett, Y.Y. Xu, K.J. Dorrington, and M.H. Klein. 1991. Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc. Natl. Acad. Sci. U.S.A 88(20):9036-9040.
16. Chung, C.H. 2008. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13(6):725-732.
17. Chung, C.H., B. Mirakhur, E. Chan, Q.T. Le, J. Berlin, M. Morse, B.A. Murphy, S.M. Satinover, J. Hosen, D. Mauro, and others. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 358(11):1109-1117.
18. Critchley, A.J. 2006. Congenital disorders of glycosylation and disease pathogenesis. D. Phil thesis. Oxford: University of Oxford.
19. Davies, J., L. Jiang, L.Z. Pan, M.J. LaBarre, D. Anderson, and M. Reff. 2001. Expression of GnTIII in a recombi-nant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74(4):288-294.
20. Deisenhofer, J. 1981. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-A resolution. Biochemistry 20(9):2361-2370.
21. Duncan, A.R., J.M. Woof, L.J. Partridge, D.R. Burton, and G. Winter. 1988. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 332(6164):563-564.
22. Dwek, R.A. 1998. Biological importance of glycosylation. Dev. Biol. Stand. 96:43-47.
23. Farooq, M., N. Takahashi, H. Arrol, M. Drayson, and R. Jefferis. 1997. Glycosylation of polyclonal and paraprotein IgG in multiple myeloma. Glycoconj. J. 14(4):489-492.
24. Ferrara, C., P. Brunker, T. Suter, S. Moser, U. Puntener, and R. Umana. 2006a. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 93(5):851-861.
25. Ferrara, C., F. Stuart, P. Sondermann, P. Brunker, and P. Umana. 2006b. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281(8):5032-5036.
26. Fujii, S., T. Nishiura, A. Nishikawa, R. Miura, and N. Taniguchi. 1990. Structural heterogeneity of sugar chains in immunoglobulin G. Conformation of immunoglobulin G molecule and substrate specificities of glycosyltrans-ferases. J. Biol. Chem. 265(11):6009-6018.
27. Gala, F.A., and S.L. Morrison. 2004. V region carbohydrate and antibody expression. J. Immunol. 172(9): 5489-5494.
28. Galili, U., F. Anaraki, A. Thall, C. Hill-Black, and M. Radic. 1993. Onepercentofhuman circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82(8):2485-2493.
29. Ghetie, V., and E.S. Ward. 2000. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu. Rev. Immunol. 18:739-766.
30. Ghirlando, R., M.B. Keown, G.A. Mackay, M.S. Lewis, J.C. Unkeless, and H.J. Gould. 1995. Stoichiometry and thermodynamics of the interaction between the Fc fragment of human IgG1 and its low-affinity receptor Fc gamma RIII. Biochemistry 34(41):13320-13327.
31. Ghirlando, R., J. Lund, M. Goodall, and R. Jefferis. 1999. Glycosylation of human IgG-Fc: Influences on structure revealed by differential scanning micro-calorimetry. Immunol. Lett. 68(1):47-52.
32. Grey, A.A., S. Narasimhan, J.R. Brisson, H. Schachter, and J.P. Carver. 1982. Structure of the glycopeptides of a human gamma 1-immunoglobulin G (Tem) myeloma protein as determined by 360-megahertz nuclear magnetic resonance spectroscopy. Can. J. Biochem. 60(12):1123-1131.
33. Guile, G.R., P.M. Rudd, D.R. Wing, S.B. Prime, and R.A. Dwek. 1996. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal. Biochem. 240(2):210-226.
34. Hamilton, S.R., P. Bobrowicz, B. Bobrowicz, R.C. Davidson, H. Li, T. Mitchell, J.H. Nett, S. Rausch, T.A. Stadheim, H. Wischnewski, and others. 2003. Production of complex human glycoproteins in yeast. Science 301(5637):1244-1246.
35. Hansske, B., C. Thiel, T. Lubke, M. Hasilik, S. Honing, V. Peters, P.H. Heidemann, G.F. Hoffmann, E.G. Berger, K. von Figura, and others. 2002. Deficiency of UDP-galactose: N-acetylglucosamine beta-1,4-galactosyl-transferase I causes the congenital disorder of glycosylation type IId. J. Clin. Invest. 109(6):725-733.
36. Hendershot, L., D. Bole, G. Kohler, and J.F. Kearney. 1987. Assembly and secretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J. Cell. Biol. 104(3):761-767.
37. Hokke, C.H., A.A. Bergwerff, G.W. van Dedem, J.P. Kamerling, and J.F. Vliegenthart. 1995. Structural analysis of the sialylated N-and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetyllactosamine units. Eur. J. Biochem. 228(3):981-1008.
38. Holland, M., K. Takada, T. Okumoto, N. Takahashi, K. Kato, D. Adu, A. Ben-Smith, L. Harper, C.O. Savage, and R. Jefferis. 2002. Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis. Clin. Exp. Immunol. 129(1):183-190.
39. Holland, M., H. Yagi, N. Takahashi, K. Kato, C.O. Savage, D.M. Goodall, and R. Jefferis. 2006. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim. Biophys. Acta 1760(4):669-677.
40. Huang, L., S. Biolsi, K.R. Bales, and U. Kuchibhotla. 2006. Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. Anal. Biochem. 349(2):197-207.
41. Ip, C.C., W.J. Miller, M. Silberklang, G.E. Mark, R.W. Ellis, L. Huang, J. Glushka, H. van Halbeek, J. Zhu, and J.A. Alhadeff. 1994. Structural characterization of the N-glycans of a humanized anti-CD18 murine immunoglobulin G. Arch. Biochem. Biophys. 308(2):387-399.
42. Itoh, K., N. Takahashi, and M. Hirayama. 1993. Abnormalities in the oligosaccharide moieties ofimmunoglobulin G in patients with mytonic dystrophy. J. Clin. Biochem. Nutr. 14:61-69.
43. Jaeken, J., and G. Matthijs. 2007. Congenital disorders of glycosylation: A rapidly expanding disease family. Annu. Rev. Genomics Hum. Genet. 8:261-278.
44. Jefferis, R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21(1):11-16.
45. Jefferis, R. 2006. A sugar switch for anti-inflammatory antibodies. Nature Biotechnol. 24(10):1230-1231.
46. Jefferis, R. 2007. Antibody therapeutics: Isotype and glycoform selection. Expert Opin. Biol. Ther. 7(9): 1401-1413.
47. Jefferis, R., J. Lund, H. Mizutani, H. Nakagawa, Y. Kawazoe, Y. Arata, and N. Takahashi. 1990. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem. J. 268(3):529-537.
48. Jones, J., S.S. Krag, and M.J. Betenbaugh. 2005. Controlling N-linked glycan site occupancy. Biochim. Biophys. Acta 1726(2):121-137.
49. Kanda, Y., T. Yamada, K. Mori, A. Okazaki, M. Inoue, K. Kitajima-Miyama, R. Kuni-Kamochi, R. Nakano, K. Yano, S. Kakita, and others. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types. Glycobiology 17(1):104-118.
50. Kaneko, Y., F. Nimmeijahn, and J.V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787):670-673.
51. Kibe, T., S. Fujimoto, C. Ishida, H. Togari, S. Okada, H. Nakagawa, Y. Tsukamoto, and N. Takahashi. 1996. Glycosylation and placental transport of IgG. J. Clin. Biochem. Nutr. 21:57-63.
52. Kim, H., Y. Yamaguchi, K. Masuda, C. Matsunaga, K. Yamamoto, T. Irimura, N. Takahashi, K. Kato, and Y. Arata. 1994. O-glycosylation in hinge region of mouse immunoglobulin G2b. J. Biol. Chem. 269(16): 12345-12350.
53. Koene, H.R., M. Kleijer, J. Algra, D. Roos, A.E. von dem Borne and M. de Haas. 1997. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90(3):1109-1114.
54. Kornfeld, R., and M. Kornfeld. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54:631-664.
55. Krapp, S., Y. Mimura, R. Jefferis, R. Huber, and P. Sondermann. 2003. Structural analysis of human IgG-Fc glyco-forms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325(5):979-989.
56. Li, H., N. Sethuraman, T.A. Stadheim, D. Zha, B. Prinz, N. Ballew, P. Bobrowicz, B.K. Choi, W.J. Cook, M. Cukan, and others. 2006. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nature Biotechnol. 24(2):210-215.
57. Lifely, M.R., C. Hale, S. Boyce, M.J. Keen, and J. Phillips. 1995. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5(8):813-822.
58. Longmore, G.D., and H. Schachter. 1982. Product-identification and substrate-specificity studies of the GDP-L-fucose: 2-acetamido-2-deoxy-beta-D-glucoside (FUC goes to Asn-linked GlcNAc) 6-alpha-L-fucosyltransfer-ase in a Golgi-rich fraction from porcine liver. Carbohydr. Res. 100:365-392.
59. Lund, J., N. Takahashi, J.D. Pound, M. Goodall, and R. Jefferis. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157(11):4963-4969.
60. Lund, J., N. Takahashi, J.D. Pound, M. Goodall, H. Nakagawa, and R. Jefferis. 1995. Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors. FASEB J. 9(1):115-119.
61. Lund, J., T. Tanaka, N. Takahashi, G. Sarmay, Y. Arata, and R. Jefferis. 1990. A protein structural change in agly-cosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol. Immunol. 27(11):1145-1153.
62. Lund, J., G. Winter, P.T. Jones, J.D. Pound, T. Tanaka, M.R. Walker, P.J. Artymiuk, Y. Arata, D.R. Burton, R. Jefferis, and others. 1991. Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG. J. Immunol. 147(8):2657-2662.
63. Maenaka, K., P.A. van der Merwe, D.I. Stuart, E.Y. Jones, and P. Sondermann. 2001. The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J. Biol. Chem. 276(48):44898-44904.
64. Malhotra, R., M.R. Wormald, P.M. Rudd, P.B. Fischer, R.A. Dwek, and R.B. Sim. 1995. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. NatureMed. 1(3):237-243.
65. Martinez, T., D. Pace, L. Brady, M. Gerhart, and A. Balland. 2007. Characterization of a novel modification on IgG2 light chain. Evidence for the presence of O-linked mannosylation. J. Chromatogr. A 1156(1-2):183-187.
66. Masuda, K., Y. Yamaguchi, K. Kato, N. Takahashi, I. Shimada, and Y. Arata. 2000. Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Lett. 473(3):349-357.
67. Matsumiya, S., Y. Yamaguchi, J. Saito, M. Nagano, H. Sasakawa, S. Otaki, M. Satoh, K. Shitara, and K. Kato. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368(3):767-779.
68. McCann, K.J., C.H. Ottensmeier, A. Callard, C.M. Radcliffe, D.J. Harvey, R.A. Dwek, P.M. Rudd, B.J. Sutton, P. Hobby, and F.K. Stevenson. 2008. Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Mol. Immunol. 45(6):1567-1572.
69. McGreal, E.P., J.L. Miller, and S. Gordon. 2005. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr. Opin. Immunol. 17(1):18-24.
70. Mimura, Y., P.R. Ashton, N. Takahashi, D.J. Harvey, and R. Jefferis. 2007. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J. Immunol. Methods 326(1-2):116-126.
71. Mimura, Y., S. Church, R. Ghirlando, P.R. Ashton, S. Dong, M. Goodall, J. Lund, and R. Jefferis. 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol. Immunol. 37(12-13):697-706.
72. Mimura, Y., P. Sondermann, R. Ghirlando, J. Lund, S.P. Young, M. Goodall, and R. Jefferis. 2001. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J. Biol. Chem. 276(49):45539-45547.
73. Nguyen, D.H., P. Tangvoranuntakul, and A. Varki. 2005. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J. Immunol. 175(1):228-236.
74. Nimmerjahn, F., R.M. Anthony, and J.V. Ravetch. 2007. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc. Natl. Acad. Sci. USA 104(20):8433-8437.
75. Nishie, T., O. Miyaishi, H. Azuma, A. Kameyama, C. Naruse, N. Hashimoto, H. Yokoyama, H. Narimatsu, T. Wada, and M. Asano. 2007. Development of immunoglobulin A nephropathy-like disease in beta-1,4-galac-tosyltransferase-I-deficient mice. Am. J. Pathol. 170(2):447-456.
76. Nose, M., and H. Wigzell. 1983. Biological significance of carbohydrate chains on monoclonal antibodies. Proc. Natl. Acad. Sci. USA 80(21):6632-6636.
77. Okazaki, A., E. Shoji-Hosaka, K. Nakamura, M. Wakitani, K. Uchida, S. Kakita, K. Tsumoto, I. Kumagai, and K. Shitara. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J. Mol. Biol. 336(5):1239-1249.
78. Padlan, E.A. 1990. X-ray diffraction studies of antibody constant regions. In Fc receptors and the action of antibodies, ed. Metzger, H. 12-30. Washington, D.C.: American Society for Microbiology.
79. Parekh, R.B., R.A. Dwek, B.J. Sutton, D.L. Fernandes, A. Leung, D. Stanworth, T.W. Rademacher, T. Mizuochi, T. Taniguchi, K. Matsuta, and others. 1985. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316(6027):452-457.
80. Parekh, R., I. Roitt, D. Isenberg, R. Dwek, and T. Rademacher. 1988. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J. Exp. Med. 167(5):1731-1736.
81. Pound, J.D., J. Lund, and R. Jefferis. 1993. Aglycosylated chimaeric human IgG3 can trigger the human phagocyte respiratory burst. Mol. Immunol. 30(3):233-241.
82. Qian, J., T. Liu, L. Yang, A. Daus, R. Crowley, and Q. Zhou. 2007. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal. Biochem. 364(1):8-18.
83. Radaev, S., S. Motyka, W.H. Fridman, C. Sautes-Fridman, and P.D. Sun. 2001. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 276(19):16469-16477.
84. Radcliffe, C.M., J.N. Arnold, D.M. Suter, M.R. Wormald, D.J. Harvey, L. Royle, Y. Mimura, Y. Kimura, R.B. Sim, S. Inoges, and others. 2007. Human follicular lymphoma cells contain oligomannose glycans in the antigenbinding site of the B-cell receptor. J. Biol. Chem. 282(10):7405-7415.
85. Raju, T.S., J.B. Briggs, S.M. Borge, and A.J. Jones. 2000. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10(5):477-486.
86. Restelli, V., and M. Butler. 2002. The effect of cell culture parameters on protein glycosylation. In Cell engineering, ed. Al-Rubeai, M. 61-92. Dordrecht: Kluwer.
87. Roopenian, D.C., and S. Akilesh. 2007. FcRn: The neonatal Fc receptor comes of age. Nature Rev. Immunol. 7(9):715-725.
88. Routier, F.H., E.F. Hounsell, P.M. Rudd, N. Takahashi, A. Bond, F.C. Hay, A. Alavi, J.S. Axford, and R. Jefferis. 1998. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: A critical evaluation of different methods. J. Immunol. Methods 213(2):113-130.
89. Royle, L., M.P. Campbell, C.M. Radcliffe, D.M. White, D.J. Harvey, J.L. Abrahams, Y.G. Kim, G.W. Henry, N.A. Shadick, M.E. Weinblatt, and others. 2008. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal. Biochem. 376(1):1-12.
90. Royle, L., C.M. Radcliffe, R.A. Dwek, and P.M. Rudd. 2006. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. MethodsMol. Biol. 347:125-143.
91. Royle, L., A. Roos, D.J. Harvey, M.R. Wormald, D. van Gijlswijk-Janssen, R.M. Redwan el, I.A. Wilson, M.R. Daha, R.A. Dwek, and P.M. Rudd. 2003. Secretory IgA N-and O-glycans provide a link between the innate and adaptive immune systems. J. Biol. Chem. 278(22):20140-20153.
92. Rudd, P.M., and R.A. Dwek. 1997. Glycosylation: Heterogeneity and the 3D structure of proteins. Crit. Rev. Biochem. Mol. Biol. 32(1):1-100.
93. Sarmay, G., J. Lund, Z. Rozsnyay, J. Gergely, and R. Jefferis. 1992. Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor. Mol. Immunol. 29(5):633-639.
94. Scallon, B.J., S.H. Tam, S.G. McCarthy, A.N. Cai, and T.S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44(7):1524-1534.
95. Sheeley, D.M., B.M. Merrill, and L.C. Taylor. 1997. Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal alpha-linked galactose. Anal. Biochem. 247(1):102-110.
96. Sheridan, C. 2007. Commercial interest grows in glycan analysis. Nature Biotechnol. 25(2):145-146.
97. Shields, R.L., J. Lai, R. Keck, L.Y. O'Connell, K. Hong, Y.G. Meng, S.H. Weikert, and L.G. Presta. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277(30):26733-26740.
98. Shields, R.L., A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, and others. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276(9):6591-6604.
99. Shinkawa, T., K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, and others. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278(5):3466-3473.
100. Sondermann, P., R. Huber, V. Oosthuizen, and U. Jacob. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406(6793):267-273.
101. Takahashi, N., H. Nakagawa, K. Fujikawa, Y. Kawamura, and N. Tomiya. 1995. Three-dimensional elution mapping of pyridylaminated N-linked neutral and sialyl oligosaccharides. Anal. Biochem. 226(1):139-146.
102. Takeuchi, M., S. Takasaki, H. Miyazaki, T. Kato, S. Hoshi, N. Kochibe, and A. Kobata. 1988. Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J. Biol. Chem. 263(8):3657-3663.
103. Tangvoranuntakul, P., P. Gagneux, S. Diaz, M. Bardor, N. Varki, A. Varki, and E. Muchmore. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. USA 100(21):12045-12050.
104. Tao, M.H., and S.L. Morrison. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143(8):2595-2601.
105. Umana, P., J. Jean-Mairet, R. Moudry, H. Amstutz, and J.E. Bailey. 1999. Engineered glycoforms of an antineur-oblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnol. 17(2):176-180.
106. van den Eijnden, D.H., D.H. Joziasse, L. Dorland, H. van Halbeek, J.F. Vliegenthart, and K. Schmid. 1980. Specificity in the enzymic transfer of sialic acid to the oligosaccharide branches of b1-and triantennary glyco-peptides of alpha 1-acid glycoprotein. Biochem. Biophys. Res. Commun. 92(3):839-845.
107. Wong, N.S., M.G. Yap, and D.I. Wang. 2006. Enhancing recombinant glycoprotein sialylation through CMP-sialic acid transporter over expression in Chinese hamster ovary cells. Biotechnol. Bioeng. 93(5):1005-1016.
108. Woof, J.M., and D.R. Burton. 2004. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Rev. Immunol. 4(2):89-99.
109. Woof, J.M., L.J. Partridge, R. Jefferis, and D.R. Burton. 1986. Localisation of the monocyte-binding region on human immunoglobulin G. Mol. Immunol. 23(3):319-330.
110. Wormald, M.R., P.M. Rudd, D.J. Harvey, S.C. Chang, I.G. Scragg, and R.A. Dwek. 1997. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 36(6):1370-1380.
111. Wright, A., and S.L. Morrison. 1998. Effect of C2-associated carbohydrate structure on Ig effector function: Studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J. Immunol. 160(7):3393-3402.
112. Wright, A., M.H. Tao, E.A. Kabat, and S.L. Morrison. 1991. Antibody variable region glycosylation: Position effects on antigen binding and carbohydrate structure. EMBO J. 10(10):2717-2723.
113. Yamada, E., Y. Tsukamoto, R. Sasaki, K. Yagyu, and N. Takahashi. 1997. Structuralchanges of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj. J. 14(3):401-405.
114. Yamaguchi, Y., K. Kato, M. Shindo, S. Aoki, K. Furusho, K. Koga, N. Takahashi, Y. Arata, and I. Shimada. 1998. Dynamics of the carbohydrate chains attached to the Fc portion of immunoglobulin G as studied by NMR spectroscopy assisted by selective 13C labeling of the glycans. J. Biomol. NMR 12(3):385-394.
115. Yamane-Ohnuki, N., S. Kinoshita, M. Inoue-Urakubo, M. Kusunoki, S. Iida, R. Nakano, M. Wakitani, R. Niwa, M. Sakurada, K. Uchida, and others. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87(5):614-622.
116. Youings, A., S.C. Chang, R.A. Dwek, and I.G. Scragg. 1996. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem. J. 314 (Pt 2):621-630.